Kimmtrak's Success | Immunocore's flagship product Kimmtrak exceeds revenue expectations, driving strong growth in the US market and positioning the company as a potential major player in oncology |
PRAME Data Anticipation | Upcoming PRAME study results in melanoma and ovarian cancer could significantly impact Immunocore's stock price, with analysts estimating potential movements of +$5-6 or -$2-10 |
Competitive Edge | Immunocore's treatments boast a strong safety profile, with no Grade 3+ CRS or ICANS, potentially outperforming competitors like Immatics' TCR-T therapy in the highly competitive oncology space |
Future Catalysts | Multiple upcoming milestones, including PRAME data updates and Phase 1 HIV treatment results, could drive Immunocore's valuation, with an average analyst price target of $66 |
Chỉ số cần so sánh | IMCR | Lĩnh vực Ngành- Số liệu trung bình từ một nhóm lớn các công ty Y Tế liên quan thuộc ngành | Mối quan hệ Mối quan hệIMCRCông TyLĩnh vực | |
---|---|---|---|---|
Tỉ số P/E | −81.6x | −1.5x | −0.6x | |
Tỷ Lệ PEG | −1.27 | 0.01 | 0.00 | |
Giá/G.Trị Sổ Sách | 4.3x | 1.1x | 2.6x | |
Giá / Doanh Số 12T | 4.7x | 9.2x | 3.3x | |
Tăng (Mục Tiêu của Nhà Phân Tích) | 85.5% | 306.8% | 40.1% | |
Giá Trị Hợp Lý Tăng | Mở Khóa | 29.6% | 5.3% | Mở Khóa |